Clinical trial
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
NCT00191750 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191750 |
|---|---|
| Title | A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned |
| Official title | Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell |
| Intervention type | Drug |
| Interventions | Pemetrexed |
| Enrollment | 80 |
| Start date | Jul 1, 2004 |
| Completion | Sep 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: